The review by Goodin and Bates in this issue 1 on treating multiple sclerosis (MS) when it might first be heralding is indeed timely for a number of reasons. First, virtually all of the first line current disease modifying drugs (interferon beta and glatiramer acetate) have now been shown to be effective at the stage called 'CIS' or the first 'clinically isolated syndrome' in reducing the chanc...

Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia is a deadly disease with no effective treatment. The purpose of this randomised prospective multicentric study was to characterise the clinical effects of interferon gamma (IFN-gamma) 1b administered subcutaneously thrice weekly versus colchicine for 2 yrs. This study had no pre-specified end-points. Fifty consecutive IPF patients...

OBJECTIVE The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-beta-1b (IFNbeta-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments. METHODS In the pivotal study, 372 patients were randomized to placebo (n = 123), IFNbeta-1b 50 microg (n = 125), or IFNbeta-1b 250 microg (n = 124) subcutaneously every other day for up to...

conclusions it can be concluded that the rsm is an effective method for the optimization of recombinant protein expression using synthetic genes in e. coli. results the proposed optimum fermentation condition consisted of 7.81 g l-1 glucose, od 600 nm prior induction 1.66 and induction temperature of 30.27°c. the model prediction of 0.267 g l-1 of rhifn-β and 0.961 g l-1 of acetate at the optim...

Hepatitis C virus (HCV) envelope glycoprotein-2 (E2) inhibits the interferon (IFN)–induced, double –stranded RNA activated protein kinase (PKR) via PKR eukaryotic initiation factor-2α phosphorylation homology domain (PePHD). Present study examined the genetic variability of the PePHD in patients receiving interferon therapy. The PePHD region from HCV genotype 1a/1b infected patients receiving I...

BACKGROUND Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS). METHODS We evaluated the impact of interferon beta-1b (IFNβ-1b) 250 µg on cognitive performance during the CIS stage in the BENEFITstudy. Cognition was assessed by Paced Auditory Serial Addition Test-3" (PASAT-3") scores. RESULTS Improvement i...

OBJECTIVE To evaluate the cost utility of interferon beta-1b in secondary progressive multiple sclerosis. DESIGN Population based cost utility model (healthcare perspective). Data on use of health services were obtained from case records and routine morbidity data and utility values from a EuroQol survey. Local and published costs were used. Effectiveness was modelled using data on relative r...

Objective To identify serum proteins associated with MS and affected by interferon beta treatment. Methods Plasma samples from 29 untreated relapsing-remitting patients 15 healthy controls were investigated a multiplexed panel containing 92 related to inflammation. Follow-up available 13 at 1 3 months after initiation of treatment beta-1a. Results Ten differentially expressed in patients. Five ...

RNA-specific adenosine deaminase (ADAR1) catalyzes the deamination of adenosine to inosine in viral and cellular RNAs. Two size forms of the ADAR1 editing enzyme are known, an IFN-inducible approximately 150-kDa protein and a constitutively expressed N-terminally truncated approximately 110-kDa protein. We have now identified alternative exon 1 structures of human ADAR1 transcripts that initiat...

Background and objective Study evaluating Betaferon(R)'s safety and tolerability in paediatric patients with multiple sclerosis (BETAPAEDIC) is a prospective, open-label observational multicentre study to assess the safety and effectiveness of interferon beta-1b in paediatric patients with relapsing-remitting multiple sclerosis. Methods Treatment-naïve patients (12-16 years) scheduled to star...